Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat on September 4, 2025, at 9:45 a.m. ET in New York City.
Investors can access a live webcast of the presentation through Nuvalent's website, where it will remain available for 30 days after the event.
Nuvalent (Nasdaq: NUVL), una società biofarmaceutica in fase clinica che sviluppa terapie oncologiche mirate, ha annunciato la sua partecipazione alla Cantor Global Healthcare Conference 2025. La dirigenza dell'azienda, tra cui il CEO James Porter, Ph.D., e la CFO Alexandra Balcom, prenderà parte a un incontro informale il 4 settembre 2025 alle 9:45 ET a New York City.
Gli investitori potranno seguire la presentazione in diretta streaming tramite il sito web di Nuvalent; il webcast resterà disponibile per 30 giorni dopo l'evento.
Nuvalent (Nasdaq: NUVL), una compañía biofarmacéutica en fase clínica que desarrolla terapias oncológicas dirigidas, ha anunciado su participación en la Cantor Global Healthcare Conference 2025. La dirección de la empresa, incluyendo al director ejecutivo James Porter, Ph.D., y la directora financiera Alexandra Balcom, participará en una charla informal el 4 de septiembre de 2025 a las 9:45 a.m. ET en la ciudad de Nueva York.
Los inversores podrán acceder a una transmisión en directo de la presentación a través del sitio web de Nuvalent; el webcast estará disponible durante 30 días después del evento.
Nuvalent (Nasdaq: NUVL), 표적 항암제 개발을 진행 중인 임상 단계 바이오제약 기업이 Cantor Global Healthcare Conference 2025에 참여한다고 발표했습니다. 회사 경영진인 CEO 제임스 포터(Ph.D.)와 CFO 알렉산드라 발콤이 2025년 9월 4일 오전 9시 45분(동부시간, ET) 뉴욕시에서 대담을 진행합니다.
투자자들은 Nuvalent 웹사이트를 통해 프레젠테이션의 실황 웹캐스트를 시청할 수 있으며, 해당 웹캐스트는 행사 후 30일간 이용 가능합니다.
Nuvalent (Nasdaq: NUVL), une société biopharmaceutique en phase clinique développant des thérapies ciblées contre le cancer, a annoncé sa participation à la Cantor Global Healthcare Conference 2025. La direction de l'entreprise, notamment le PDG James Porter, Ph.D., et la directrice financière Alexandra Balcom, participera à une discussion informelle le 4 septembre 2025 à 9h45 (ET) à New York City.
Les investisseurs pourront suivre la présentation en webcast en direct sur le site web de Nuvalent ; le replay restera disponible pendant 30 jours après l'événement.
Nuvalent (Nasdaq: NUVL), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das zielgerichtete Krebstherapien entwickelt, hat seine Teilnahme an der Cantor Global Healthcare Conference 2025 angekündigt. Die Unternehmensführung, darunter CEO James Porter, Ph.D., und CFO Alexandra Balcom, wird am 4. September 2025 um 9:45 Uhr ET in New York City an einem Gespräch teilnehmen.
Investoren können die Präsentation als Live-Webcast über die Website von Nuvalent verfolgen; der Webcast steht für 30 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-cantor-global-healthcare-conference-2025-302540438.html
SOURCE Nuvalent, Inc.
FAQ
When is Nuvalent (NUVL) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent Nuvalent at the Cantor Global Healthcare Conference 2025?
How can investors access Nuvalent's presentation at the Cantor conference?
What type of company is Nuvalent (NUVL)?
